Tela Bio, Inc. Stock Price, News & Analysis

TELA Bio, a commercial-stage medical technology company, reported a revenue of $11.2 million for Q3 2022, marking a 46% increase year-over-year. The company highlighted rising demand for its OviTex products, achieving 29% and 108% revenue growth for OviTex and OviTex PRS, respectively. They completed a public offering that netted $34.4 million. Despite increased operating expenses totaling $16.8 million, TELA Bio anticipates steady recovery in procedure volumes post-COVID-19 and projects full-year revenue between $42 million and $45 million, representing 43%-53% growth over 2021.

TELA Bio, Inc., a medical technology company, will participate in the Canaccord MedTech, Diagnostics and Digital Health & Services Forum on November 17, 2022, at 1:30 PM ET. The forum aims to showcase innovative soft-tissue reconstruction solutions that prioritize patient anatomy restoration. Interested parties can access the presentation live or archived at ir.telabio.com. TELA's mission focuses on leveraging the patient’s natural healing response while minimizing the use of synthetic materials.

TELA Bio, Inc. announced the approval of inducement grants for 54,600 stock options and 7,500 restricted stock units to 11 new employees. The grants were made under Nasdaq Rule 5635(c)(4) and are part of the new hires' compensation packages as an inducement for their employment. The stock options have an exercise price of $9.00 per share and will vest over four years. The restricted stock units will also vest in equal annual installments over the same period. These equity awards are contingent on continued service with TELA Bio.

TELA Bio, Inc. (TELA) announced it will report its third quarter 2022 financial results on November 9, 2022, followed by a conference call at 4:30 p.m. ET. The company focuses on innovative soft-tissue reconstruction solutions, prioritizing patient anatomy preservation. The results will include financial metrics that are crucial for investors. Interested participants need to register in advance to join the call and can access a replay through TELA's investor section online.

TELA Bio announced positive outcomes from the BRAVO Study, showcasing a low recurrence rate of just 2.6% for ventral hernia repairs using OviTex 1S. The two-year study, published in Annals of Medicine and Surgery, involved 92 patients and demonstrated significant improvements in patient quality of life from as early as three months post-surgery. Despite a 38% surgical site occurrence rate among predominantly high-risk patients, the data supports OviTex's efficacy as a viable alternative to traditional synthetic meshes.

TELA Bio, a commercial-stage medical technology company, has announced its participation in two investor conferences. TELA’s management will present virtually at the H.C. Wainwright Annual Global Investment Conference on September 12, 2022, at 7:00 AM ET. Additionally, they will take part in the Lake Street BIG6 1x1 Conference on September 14, 2022. TELA Bio focuses on innovative soft-tissue reconstruction solutions that prioritize patient anatomy preservation. The company is committed to enhancing clinical outcomes while reducing reliance on synthetic materials.

TELA Bio, Inc. is set to participate in the Inaugural Gilmartin Group Emerging Growth Company Showcase on August 31, 2022, at 8:30 AM ET. This commercial-stage medical technology company focuses on innovative soft-tissue reconstruction solutions that enhance clinical outcomes by preserving the patient’s anatomy. Interested parties can access the live and archived webcast through the company’s investor relations page. TELA is committed to offering cost-effective technologies that leverage natural healing while minimizing reliance on synthetic materials.

TELA Bio, Inc. has successfully closed its public offering of 4,600,000 shares of common stock at $8.00 per share, generating gross proceeds of $36.8 million. This includes 600,000 shares from the underwriter's option. The proceeds will be utilized for working capital, research and development, and various corporate purposes. The offering was registered under Form S-3 with the SEC. Lake Street Capital Markets, LLC served as the sole book-running manager for this offering.

TELA Bio, Inc. has announced the pricing of its public offering of 4,000,000 shares of common stock at $8.00 per share, aiming for gross proceeds of $32 million. Additionally, the underwriter has a 30-day option to purchase up to 600,000 shares at the same price. The offering, set to close around August 18, 2022, will fund working capital, R&D, and potential acquisitions. The offering is registered under a previously established shelf registration effective since December 29, 2020.